Synthesis and Biopharmaceutical Evaluation of Imatinib Analogues Featuring Unusual Structural Motifs

ChemMedChem

Volumn 11, Issue 1, 2016, Pages 31-37

  Nicolaou, Kyriacos C ^a   Vourloumis, Dionisios ^a   Totokotsopoulos, Sotirios ^a   Papakyriakou, Athanasios ^b   Karsunky, Holger ^c   Fernando, Hanan ^c   Gavrilyuk, Julia ^c   Webb, Damien ^d   Stepan, Antonia F ^d  

^a RICE UNIVERSITY   (United States)

^b INSTITUTE OF NANOSCIENCE AND NANOTECHNOLOGY   (Greece)

^c Stemcentrx   (United States)

^d PFIZER INC   (United States)

Author keywords

anticancer agents; biopharmaceuticals; cubane and bicyclo 1.1.1 pentanes; gleevec; imatinib analogues

Indexed keywords

ABL1 KINASE; BICYCLO COMPOUND; CUBANE DERIVATIVE; CYCLOPENTANE DERIVATIVE; DRUG ANALOG; IMATINIB; IMATINIB ANALOG; PHENYL GROUP; PHOSPHOTRANSFERASE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; BCR ABL PROTEIN; BCR-ABL1 FUSION PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR;

ARTICLE; DRUG CYTOTOXICITY; DRUG SCREENING; DRUG SOLUBILITY; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN; HUMAN CELL; K562 CELL LINE; MOLECULAR MODEL; PRIORITY JOURNAL; STEREOCHEMISTRY; STRUCTURE ACTIVITY RELATION; THERMODYNAMICS; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CELL PROLIFERATION; CHEMICAL STRUCTURE; CHEMISTRY; DOSE RESPONSE; DRUG EFFECTS; METABOLISM; SYNTHESIS; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; FUSION PROTEINS, BCR-ABL; HUMANS; IMATINIB MESYLATE; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PROTEIN KINASE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84954025944     PISSN: 18607179     EISSN: 18607187     Source Type: Journal    
DOI: 10.1002/cmdc.201500510     Document Type: Article

References (40)

1. A. Levitzki, E. Mishani, Annu. Rev. Biochem. 2006, 75, 93-109;
2. T. Hunter, J. Clin. Invest. 2007, 117, 2036-2043.
3. A. Levitzki, Annu. Rev. Pharmacol. Toxicol. 2013, 53, 161-185.
4. F. Lovering, J. Bikker, C. Humblet, J. Med. Chem. 2009, 52, 6752-6756.
5. Values for clog P were calculated using the clog P program (version4.3) from BioByte Corp. (Claremont, USA); www.biobyte.com.
6. Martindale: The Complete Drug Reference, 36thed. (Ed.:, S.C. Sweetman,), Pharmaceutical Press, London, 2009, p. 733.
7. For a recent Essay on this topic, see:, K. C. Nicolaou, Angew. Chem. Int. Ed. 2014, 53, 9128-9140;
8. Angew. Chem. 2014, 126, 9280-9292 and references therein.
9. A. F. Stepan, C. Subramanyam, I. V. Efremov, J. K. Dutra, T. J. OSullivan, K. J. DiRico, W. S. McDonald, A. Won, P. H. Dorff, C. E. Nolan, S. L. Becker, L. R. Pustilnik, D. R. Riddell, G. W. Kauffman, B. L. Kormos, L. Zhang, Y. Lu, S. H. Capetta, M. E. Green, K. Karki, E. Sibley, K. P. Atchison, A. J. Hallgren, C. E. Oborski, A. E. Robshaw, B. Sneed, C. J. O′Donnell, J. Med. Chem. 2012, 55, 3414-3424.
10. J. Wlochal, R. D. M. Davies, J. Burton, Org. Lett. 2014, 16, 4094-4097.
11. O. Loiseleur, D. Kaufmann, S. Abel, H. M. Buerger, M. Meisenbach, B. Schmitz, G. Sedelmeier, (Novartis Pharma GmbH, Germany), PCT Pat. Appl. WO/2003/066613A1, 2003.
12. J. Zimmermann, E. Buchdunger, H. Mett, T. Meyer, N. B. Lydon, P. Traxler, Bioorg. Med. Chem. Lett. 1996, 6, 1221-1226.
13. Y. F. Liu, C. L. Wang, Y. J. Bai, N. Han, J. P. Jiao, X. L. Qi, Org. Process Res. Dev. 2008, 12, 490-495.
14. A. F. Abdel-Magid, K. G. Carson, B. D. Harris, C. A. Maryanoff, R. D. Shah, J. Org. Chem. 1996, 61, 3849-3862.
15. Y. F. Liu, Y. J. Bai, J. Zhang, Y. Y. Li, J. P. Jiao, X. L. Qi, Eur. J. Org. Chem. 2007, 6084-6088.
16. J. B. Aggen, T. Church, R. Kasar, M. S. Linsell, Q. Lu, H. E Moser, P. A. Patten, D. Wang, (Achaogen, Inc., USA), PCT Pat. Appl. WO/2012/154204A1.
17. R. H. Perry, Jr., J. Org. Chem. 1959, 24, 829-833.
18. R. Chênevert, R. Martin, Tetrahedron: Asymmetry 1992, 3, 199-200.
19. M. L. Ingalsbe, J. D. St. Denis, J. L. Gleason, J. P. Savage, R. Priefer, Synthesis 2010, 98-102.
20. Y. Kazuta, A. Matsuda, S. Shuto, J. Org. Chem. 2002, 67, 1669-1677.
21. N. M. Yoon, C. S. Pak, J. Org. Chem. 1973, 38, 2786-2792.
22. A. B. Charette, B. Côté, J. Am. Chem. Soc. 1995, 117, 12721-12732.
23. E. Enholm, A. Joshi, D. L. Wright, Bioorg. Med. Chem. Lett. 2005, 15, 5262-5265.
24. A. J. Mancuso, S.-L. Huang, D. Swern, J. Org. Chem. 1978, 43, 2480-2482;
25. K. Omura, D. Swern, Tetrahedron 1978, 34, 1651-1660.
26. D. B. Dess, J. C. Martin, J. Org. Chem. 1983, 48, 4155-4156.
27. CCDC 1421073 contains the supplementary crystallographic data for this paper. These data are provided free of charge by The Cambridge Crystallographic Data Centre.
28. M. A. Walker, Expert Opin. Drug Discovery 2014, 9, 1421-1433;
29. T. J. Ritchie, S. J. F. Macdonald, Drug Discovery Today 2009, 14, 1011-1020.
30. R. Docherty, K. Pencheva, Y. A. Abramov, J. Pharm. Pharmacol. 2015, 67, 847-856.
31. N. Jain, S. H. Yalkowsky, J. Pharm. Sci. 2001, 90, 234-252.
32. The melting point of imatinib determined in our laboratory (204 C) lies in the same range as those previously reported:
33. 207-210 C: Ref.[11];
34. 206-210 C:, A. S. Ivanov, S. V. Shishkov, Monatsh. Chem. 2009, 140, 619-623;
35. 210-212 C:, H.-Y. Liu, W.-P. Xia, Y. Luo, W. Lu, Monatsh. Chem. 2010, 141, 907-911;
36. 208-209 C:, K.-E. Kil, Y.-S. Ding, K.-S. Lin, D. Alexoff, S. W. Kim, C. Shea, Y. Xu, L. Muench, J. S. Fowler, Nucl. Med. Biol. 2007, 34, 153-163.
37. Although each analogue was determined to be crystalline by powder X-ray diffraction studies (see Supporting Information), it is important to note that characterization of the crystal form of each analogue was not undertaken. Although it is known that different crystal forms can impact thermodynamic solubility, the thermodynamic solubility of different polymorphs is typically within two- to fivefold, see:, M. Pudipeddi, A. T. M. Serajuddin, J. Pharm. Sci. 2005, 94, 929-939.
38. E. Callegari, B. Malhotra, P. J. Bungay, R. Webster, K. S. Fenner, S. Kempshall, J. L. Laperle, M. C. Michel, G. G. Kay, Br. J. Clin. Pharmacol. 2011, 72, 235-246.
39. N. A. Hosea, W. T. Collard, S. Cole, T. S. Maurer, R. X. Fang, H. Jones, S. M. Kakar, Y. Nakai, B. J. Smith, R. Webster, K. Beaumont, J. Clin. Pharmacol. 2009, 49, 513-533.
40. S. W. Cowan-Jacob, G. Fendrich, A. Floersheimer, P. Furet, J. Liebetanz, G. Rummel, P. Rheinberger, M. Centeleghe, D. Fabbro, P. W. Manley, Acta Crystallogr. Sect. D 2007, 63, 80-93.